United States Patent 11,786,531: Zanubrutinib CYP3A-Inducer Claims, Scope and Patent Landscape
U.S. Patent No. 11,786,531 protects specific methods of using zanubrutinib, marketed as Brukinsa, when a patient with a listed B-cell malignancy must receive a moderate CYP3A inducer. The core protected regimen is zanubrutinib at approximately 640 mg per day, generally 320 mg twice daily, administered concomitantly with the inducer.
The patent is a narrow clinical-use patent rather than a composition-of-matter patent. Its commercial value depends on whether the product label, prescribing practice, or a generic or competing BTK inhibitor product directs or encourages the claimed dose adjustment. The claims cover CLL, SLL, WM, MCL, MZL and FL, and expressly identify seven moderate CYP3A inducers: rifabutin, bosentan, efavirenz, etravirine, modafinil, phenobarbital and nafcillin.
What does U.S. Patent 11,786,531 protect?
The patent has three independent method claims:
| Independent claim |
Required patient-selection step |
Required treatment |
Covered diseases |
| Claim 1 |
Patient is receiving a moderate CYP3A inducer |
Concomitant zanubrutinib at about 640 mg total daily dose |
CLL, SLL, WM, MCL, MZL or FL |
| Claim 11 |
Determine whether patient is receiving a moderate CYP3A inducer; treat if present |
Concomitant zanubrutinib at about 640 mg total daily dose |
CLL, SLL, WM, MCL, MZL or FL |
| Claim 21 |
Assess whether the inducer can be avoided; if not, treat concomitantly |
Concomitant zanubrutinib at about 640 mg total daily dose |
CLL, SLL, WM, MCL, MZL or FL |
The practical center of gravity is the combination of four elements:
- A patient has one of the claimed B-cell malignancies.
- The patient is taking, or cannot avoid taking, a moderate CYP3A inducer.
- Zanubrutinib is administered at about 640 mg per day.
- The two therapies are administered concomitantly.
The patent does not claim zanubrutinib generally, the 160 mg twice-daily regimen generally, or every drug interaction involving zanubrutinib. It targets a dose-adjustment protocol for a defined pharmacokinetic problem.
How do the dependent claims narrow the patent?
Claims 2 and 12 and 22 specify administration at approximately 320 mg twice daily. The twice-daily formulation is commercially important because it is the most direct clinical implementation of the claimed total daily dose.
Disease-specific dependent claims identify:
- CLL: claims 3, 13 and 23
- SLL: claims 4, 14 and 24
- WM: claims 5, 15 and 25
- MCL: claims 6, 16 and 26
- MZL: claims 7, 17 and 27
The independent claims also include FL, but the supplied dependent claims do not separately recite FL. That distinction matters in claim construction and infringement analysis. A product or clinical protocol directed to FL can still fall within claims 1, 11 or 21 if all other limitations are met.
Claims 8, 18 and 28 identify the moderate CYP3A inducers:
| Listed inducer |
Potential claim relevance |
| Rifabutin |
Directly recited |
| Bosentan |
Directly recited |
| Efavirenz |
Directly recited |
| Etravirine |
Directly recited |
| Modafinil |
Directly recited |
| Phenobarbital |
Directly recited |
| Nafcillin |
Directly recited |
A claim does not necessarily require one of these seven drugs unless the accused conduct is evaluated under the corresponding dependent claim. The independent claims use the broader category of a “moderate CYP3A inducer.”
What clinical comparison does Patent 11,786,531 include?
Claims 9, 19 and 29 add a comparative clinical outcome. They require that the zanubrutinib regimen:
- Prolong PFS compared with a comparable patient receiving ibrutinib at 420 mg once daily; or
- Produce a lower rate of atrial fibrillation or atrial flutter than that comparator.
These are narrower claims than the core dosing claims. The comparison introduces additional factual and evidentiary questions, including how “comparable patient” is defined, whether the comparison is based on a clinical trial or other evidence, and whether the claimed result is a required limitation or an intended result under the applicable claim-construction analysis.
The comparative claims are commercially relevant because ibrutinib is the principal first-generation covalent BTK inhibitor comparator in the patent and in the clinical literature. Zanubrutinib’s development program emphasized BTK selectivity and cardiovascular tolerability relative to ibrutinib. FDA labeling for Brukinsa identifies atrial fibrillation and flutter among clinically relevant adverse reactions, while clinical studies have reported differences in cardiovascular event rates across BTK inhibitors. Those results do not automatically establish infringement of claims 9, 10, 19, 20, 29 or 30. The specific comparator population and evidence must satisfy the claim language.[1][2]
Why is the CYP3A-inducer dosing issue commercially important?
Zanubrutinib is metabolized primarily through CYP3A. CYP3A inducers can reduce systemic exposure and potentially reduce therapeutic activity. The FDA-approved Brukinsa prescribing information addresses concomitant use with CYP3A inhibitors and inducers and provides dose-management instructions for situations in which an interacting medicine cannot be avoided.[1]
The patent’s 640 mg daily regimen is therefore directed to a clinically defined exception to the standard regimen. Brukinsa has generally been administered at:
- 160 mg twice daily; or
- 320 mg once daily,
depending on the formulation and labeling applicable to the indication and date. The patent focuses on an increased total daily dose of approximately 640 mg, generally 320 mg twice daily, when a moderate inducer is present.
This creates a potential intersection between patent scope and FDA labeling. If the approved label instructs physicians to increase zanubrutinib to 320 mg twice daily in the presence of a moderate CYP3A inducer, the label may provide evidence of induced infringement or contributory infringement theories against a manufacturer, subject to the product’s exact label and the requirements of 35 U.S.C. § 271.[3]
What is the Orange Book status of Patent 11,786,531?
The Orange Book is the FDA’s listing of patents and exclusivity for approved drug products. Patent 11,786,531 should be evaluated against the Orange Book entries for Brukinsa, including the listed active ingredient, dosage-form, formulation and method-of-use patents.[4]
A method-of-use patent can be listed in the Orange Book if it claims an approved method of using the drug. Its listing can require an abbreviated new drug application applicant to make a patent certification, including a Paragraph IV certification if the applicant asserts that the patent is invalid, unenforceable or will not be infringed.[5]
The supplied claim set is directed to a method of use, not to:
- Zanubrutinib’s chemical structure;
- A crystalline form;
- A tablet composition;
- A capsule composition;
- A general BTK-inhibition method;
- A manufacturing process; or
- A broad treatment method without the CYP3A-inducer limitation.
The commercial significance of an Orange Book listing depends on whether the patent is listed for the relevant Brukinsa strength and dosage form and whether its use code corresponds to the approved CYP3A-inducer dosing instruction. A Paragraph IV notice can trigger patent litigation and, if statutory conditions are met, a 30-month stay of FDA approval under the Hatch-Waxman framework.[5]
When does Patent 11,786,531 lose exclusivity?
The patent’s expiration date cannot be determined from the claims alone. The legally operative term depends on the patent’s earliest effective nonprovisional or international filing date, terminal disclaimers, patent-term adjustment, patent-term extension and any applicable patent-term calculations under 35 U.S.C. §§ 154 and 156.[3]
The relevant term analysis is:
| Term issue |
Relevance |
| Earliest effective filing date |
Establishes the base 20-year patent term |
| Patent-term adjustment |
Can extend the term for qualifying USPTO delay |
| Terminal disclaimer |
Can limit the patent to the expiration of another patent |
| Patent-term extension |
May apply only in statutory circumstances tied to regulatory review |
| Patent-term restoration or pediatric exclusivity |
May affect effective market protection |
| Post-grant proceedings or litigation |
Can cancel, amend or limit claims before nominal expiration |
The patent’s issue date, December 2023, does not itself determine the expiration date. A reliable freedom-to-operate conclusion requires the patent’s continuity data, terminal-disclaimer record and USPTO term calculation.[6]
How strong is the patent estate for the CYP3A-inducer regimen?
The patent is strongest against conduct that closely follows the literal claim language:
- One of the six named diseases, or FL under an independent claim;
- A recognized moderate CYP3A inducer;
- Concomitant administration;
- Approximately 640 mg total daily zanubrutinib;
- A clinical or prescribing protocol that expressly directs the regimen.
The estate is weaker where the conduct differs materially from the claims:
- Zanubrutinib is administered at 320 mg once daily rather than 320 mg twice daily;
- The interacting drug is classified as a strong or weak rather than moderate CYP3A inducer;
- The dose is adjusted by a different amount;
- The patient has a disease outside the claimed list;
- The inducer is discontinued before zanubrutinib administration;
- The treatment is not concomitant;
- The accused product label does not encourage the patented method.
The use of “about” introduces a scope question around dose variance. A court would typically assess the intrinsic evidence, specification, prosecution history and accepted clinical dosing conventions. A materially different daily dose may avoid literal infringement, but the doctrine of equivalents could become relevant depending on prosecution history and the reason for the claimed numerical range.
What Paragraph IV challenges could target the patent?
A generic applicant seeking approval for zanubrutinib may challenge the patent through a Paragraph IV certification if the patent is listed against the reference product and the applicant’s proposed labeling would cover the patented use.
Potential invalidity theories could include:
| Theory |
Potential issue |
| Anticipation |
Whether one prior-art reference discloses the full inducer, disease, concomitant-use and 640 mg regimen |
| Obviousness |
Whether dose escalation in the presence of CYP3A induction would have been predictable with a reasonable expectation of success |
| Written description |
Whether the patent adequately supports all listed diseases, inducers and dose combinations |
| Enablement |
Whether the specification enables the full breadth without undue experimentation |
| Indefiniteness |
Meaning of “about,” “moderate CYP3A inducer,” “comparable patient” and “prolongs” |
| Double patenting |
Whether the claims improperly overlap with an earlier related patent |
| Inequitable conduct |
Whether material information was withheld or misrepresented during prosecution |
The patent holder could respond that the claimed regimen is not a routine dose adjustment because CYP3A induction can materially reduce exposure, and that the specification and clinical pharmacology data support a specific compensating dose. The comparative PFS and atrial-fibrillation claims may face separate enablement, written-description and proof issues because they require an outcome relative to an ibrutinib comparator.
What patent litigation affects Brukinsa and zanubrutinib?
Zanubrutinib is associated with BeiGene, Ltd. and its U.S. commercial operations. Brukinsa has accumulated patent protection across several categories, including composition, formulations, treatment methods and pharmacokinetic or drug-interaction uses.[1][4]
Patent 11,786,531 should be separated from litigation involving:
- The zanubrutinib active ingredient;
- Solid-state or crystalline forms;
- Tablet or capsule formulations;
- General use in WM, MCL, MZL, CLL or SLL;
- BTK-inhibitor combination therapy;
- Manufacturing or process patents;
- Other CYP3A-interaction patents.
A litigation search should track the patent’s USPTO prosecution history, the FDA Orange Book listing, district-court complaints, ANDA notices, claim-construction rulings, inter partes review petitions and any terminal-disclaimer relationship. The supplied claims do not establish that the patent has been litigated, challenged in an inter partes review, or settled.
How does this patent compare with competing BTK-inhibitor patent estates?
| Product |
Active ingredient |
Relevant interaction issue |
Patent-landscape distinction |
| Brukinsa |
Zanubrutinib |
CYP3A inducers and inhibitors can alter exposure |
Patent 11,786,531 targets a 640 mg daily inducer regimen |
| Imbruvica |
Ibrutinib |
Extensive CYP3A interaction management |
420 mg once-daily ibrutinib is the express comparator in certain claims |
| Calquence |
Acalabrutinib |
CYP3A inhibitors and inducers affect exposure |
Separate composition, formulation and method-of-use estate |
| Jaypirca |
Pirtobrutinib |
CYP3A and transporter interactions |
Later-generation BTK inhibitor with separate regulatory and patent protection |
The patent does not block use of ibrutinib, acalabrutinib or pirtobrutinib. It can become relevant when a company markets zanubrutinib with labeling or promotional material that recommends the claimed dose in the presence of a moderate inducer.
What generic entry risks exist for Brukinsa?
Generic entry risk has two distinct dimensions.
First, a generic applicant may avoid the patent through a labeling carve-out that excludes the CYP3A-inducer regimen. That approach depends on whether the carved-out labeling remains adequate for FDA approval and whether the generic’s conduct nevertheless induces use of the patented method.
Second, a generic applicant may challenge the patent under Paragraph IV. The likely pressure points are the breadth of the moderate-inducer category, the “about 640 mg” limitation, the clinical significance of dose escalation and the predictability of the regimen from prior pharmacokinetic knowledge.
A launch before patent expiry could expose the applicant to infringement litigation, an injunction risk and damages. A launch after a final invalidity ruling, noninfringement ruling or settlement would present a different risk profile.
What manufacturing and geographic barriers remain?
Patent 11,786,531 does not claim a manufacturing process, raw-material route or solid-state form. It therefore does not independently create a manufacturing barrier to producing zanubrutinib. Manufacturing freedom to operate must be assessed against separate patents covering:
- The active pharmaceutical ingredient;
- Intermediates;
- Crystalline or polymorphic forms;
- Tablet and capsule compositions;
- Coatings and excipients;
- Manufacturing processes;
- Analytical methods; and
- Supplier or license agreements.
The patent is a U.S. right. Equivalent applications or granted patents in Europe, China, Japan, Canada, Australia and other markets require separate analysis. U.S. claim scope cannot be imported into foreign jurisdictions without examining the local prosecution record, granted claims, term and regulatory linkage system.
What is the commercial exposure of the patent?
The exposure is concentrated in patients requiring a moderate CYP3A inducer while receiving zanubrutinib for one of the listed B-cell malignancies. The patent does not cover the entire Brukinsa market. Its value is therefore narrower than a composition patent or a broad indication patent.
The exposure rises if:
- The FDA label expressly recommends 320 mg twice daily with moderate inducers;
- Moderate-inducer use is common in oncology patients;
- Generic labeling reproduces the dose-adjustment instruction;
- The label includes all or most of the claimed diseases;
- The patent is listed in the Orange Book;
- The patent term extends beyond composition or formulation protection; and
- No practical therapeutic substitute avoids the interaction.
It falls if clinicians commonly discontinue or replace the inducer, use an alternative BTK inhibitor, apply a different zanubrutinib dose, or treat a disease outside the claims.
Key Takeaways
- U.S. Patent 11,786,531 is a method-of-use patent centered on zanubrutinib at approximately 640 mg daily, usually 320 mg twice daily, during treatment with a moderate CYP3A inducer.
- Claims 1, 11 and 21 establish three versions of the same clinical protocol: concomitant use, screening for inducer use, and assessing whether the inducer can be avoided.
- The claimed diseases are CLL, SLL, WM, MCL, MZL and FL.
- The expressly named inducers are rifabutin, bosentan, efavirenz, etravirine, modafinil, phenobarbital and nafcillin.
- Claims 9, 10, 19, 20, 29 and 30 add comparisons to ibrutinib 420 mg once daily involving PFS or atrial fibrillation/flutter.
- The patent does not claim zanubrutinib generally, its chemical structure, its formulation or its manufacturing process.
- Orange Book listing, approved use codes, continuity data, terminal disclaimers and the official patent-term calculation determine the patent’s practical regulatory and exclusivity impact.
- Generic risk is highest if an ANDA label recommends the patented 320 mg twice-daily regimen and lowest if the use can be lawfully carved out or avoided.
- The patent’s strength is concentrated but potentially meaningful because the claimed dose adjustment may track FDA-approved prescribing instructions.
FAQs
Does Patent 11,786,531 cover the standard 160 mg twice-daily Brukinsa dose?
No. The supplied claims require approximately 640 mg total daily zanubrutinib, with dependent claims specifying approximately 320 mg twice daily.
Does the patent cover zanubrutinib treatment for follicular lymphoma?
Yes, follicular lymphoma is included in the independent claims. The supplied dependent claims separately identify CLL, SLL, WM, MCL and MZL but do not separately recite FL.
Can a generic avoid the patent by omitting moderate CYP3A-inducer language?
Potentially, if the FDA-approved labeling can be carved out and the generic’s label and conduct do not encourage the patented method. The result depends on the final label and the infringement theory.
Are claims comparing zanubrutinib with ibrutinib automatically infringed whenever zanubrutinib has better outcomes?
No. The claimed comparison requires the specified patient-treatment context, comparator dose and claimed clinical result. Evidence must establish the applicable claim limitations.
Does this patent block manufacture of zanubrutinib outside the United States?
No. The claims provided are U.S. method claims. They do not independently block API manufacture, formulation manufacture or sales outside the United States.
References
-
U.S. Food and Drug Administration. (2024). Brukinsa (zanubrutinib) prescribing information. BeiGene USA, Inc.
-
Tam, C. S., Opat, S., D’Sa, S., Jurczak, W., Lee, H.-P., Cull, G., Owen, R. G., Tedeschi, A., Brown, J. R., Marlton, P., et al. (2020). A randomized phase 3 trial of zanubrutinib versus ibrutinib in symptomatic Waldenström macroglobulinemia. Blood, 136(18), 2038-2050.
-
United States Code. (2024). 35 U.S.C. §§ 154, 156 and 271.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
-
United States Code. (2024). 21 U.S.C. § 355(j).
-
United States Patent and Trademark Office. (2024). Patent term adjustment and patent term extension resources.